Transcenta to Present Two Phase I Clinical Trials of TST001 at Upcoming ASCO GI and IGCC

SUZHOU, China: SUZHOU, China, Jan. 12, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the TST001 US Phase I Trial has been selected as a Trial in Progress poster presentation...

Click to view original post